Potential for developing a SARS-CoV receptor-binding domain (RBD) recombinant protein as a heterologous human vaccine against coronavirus infectious disease (COVID)-19.
Identifieur interne : 000393 ( Main/Merge ); précédent : 000392; suivant : 000394Potential for developing a SARS-CoV receptor-binding domain (RBD) recombinant protein as a heterologous human vaccine against coronavirus infectious disease (COVID)-19.
Auteurs : Wen-Hsiang Chen [États-Unis] ; Peter J. Hotez [États-Unis] ; Maria Elena Bottazzi [États-Unis]Source :
- Human vaccines & immunotherapeutics [ 2164-554X ] ; 2020.
Abstract
A SARS-CoV receptor-binding domain (RBD) recombinant protein was developed and manufactured under current good manufacturing practices in 2016. The protein, known as RBD219-N1 when formulated on Alhydrogel®, induced high-level neutralizing antibodies and protective immunity with minimal immunopathology in mice after a homologous virus challenge with SARS-CoV (MA15 strain). We examined published evidence in support of whether the SARS-CoV RBD219-N1 could be repurposed as a heterologous vaccine against Coronavirus Infectious Disease (COVID)-19. Our findings include evidence that convalescent serum from SARS-CoV patients can neutralize SARS-CoV-2. Additionally, a review of published studies using monoclonal antibodies (mAbs) raised against SARS-CoV RBD and that neutralizes the SARS-CoV virus in vitro finds that some of these mAbs bind to the receptor-binding motif (RBM) within the RBD, while others bind to domains outside this region within RBD. This information is relevant and supports the possibility of developing a heterologous SARS-CoV RBD vaccine against COVID-19, especially due to the finding that the overall high amino acid similarity (82%) between SARS-CoV and SARS-CoV-2 spike and RBD domains is not reflected in RBM amino acid similarity (59%). However, the high sequence similarity (94%) in the region outside of RBM offers the potential of conserved neutralizing epitopes between both viruses.
DOI: 10.1080/21645515.2020.1740560
PubMed: 32298218
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000081
- to stream PubMed, to step Curation: 000081
- to stream PubMed, to step Checkpoint: 000321
- to stream Ncbi, to step Merge: 003B13
- to stream Ncbi, to step Curation: 003B13
- to stream Ncbi, to step Checkpoint: 003B13
Links to Exploration step
pubmed:32298218Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Potential for developing a SARS-CoV receptor-binding domain (RBD) recombinant protein as a heterologous human vaccine against coronavirus infectious disease (COVID)-19.</title>
<author><name sortKey="Chen, Wen Hsiang" sort="Chen, Wen Hsiang" uniqKey="Chen W" first="Wen-Hsiang" last="Chen">Wen-Hsiang Chen</name>
<affiliation wicri:level="2"><nlm:affiliation>Texas Children's Hospital Center for Vaccine Development, Departments of Pediatrics, Baylor College of Medicine, Houston, TX, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Texas Children's Hospital Center for Vaccine Development, Departments of Pediatrics, Baylor College of Medicine, Houston, TX</wicri:regionArea>
<placeName><region type="state">Texas</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hotez, Peter J" sort="Hotez, Peter J" uniqKey="Hotez P" first="Peter J" last="Hotez">Peter J. Hotez</name>
<affiliation wicri:level="2"><nlm:affiliation>Texas Children's Hospital Center for Vaccine Development, Departments of Pediatrics, Baylor College of Medicine, Houston, TX, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Texas Children's Hospital Center for Vaccine Development, Departments of Pediatrics, Baylor College of Medicine, Houston, TX</wicri:regionArea>
<placeName><region type="state">Texas</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Bottazzi, Maria Elena" sort="Bottazzi, Maria Elena" uniqKey="Bottazzi M" first="Maria Elena" last="Bottazzi">Maria Elena Bottazzi</name>
<affiliation wicri:level="2"><nlm:affiliation>Texas Children's Hospital Center for Vaccine Development, Departments of Pediatrics, Baylor College of Medicine, Houston, TX, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Texas Children's Hospital Center for Vaccine Development, Departments of Pediatrics, Baylor College of Medicine, Houston, TX</wicri:regionArea>
<placeName><region type="state">Texas</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32298218</idno>
<idno type="pmid">32298218</idno>
<idno type="doi">10.1080/21645515.2020.1740560</idno>
<idno type="wicri:Area/PubMed/Corpus">000081</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000081</idno>
<idno type="wicri:Area/PubMed/Curation">000081</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000081</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000321</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000321</idno>
<idno type="wicri:Area/Ncbi/Merge">003B13</idno>
<idno type="wicri:Area/Ncbi/Curation">003B13</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">003B13</idno>
<idno type="wicri:Area/Main/Merge">000393</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Potential for developing a SARS-CoV receptor-binding domain (RBD) recombinant protein as a heterologous human vaccine against coronavirus infectious disease (COVID)-19.</title>
<author><name sortKey="Chen, Wen Hsiang" sort="Chen, Wen Hsiang" uniqKey="Chen W" first="Wen-Hsiang" last="Chen">Wen-Hsiang Chen</name>
<affiliation wicri:level="2"><nlm:affiliation>Texas Children's Hospital Center for Vaccine Development, Departments of Pediatrics, Baylor College of Medicine, Houston, TX, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Texas Children's Hospital Center for Vaccine Development, Departments of Pediatrics, Baylor College of Medicine, Houston, TX</wicri:regionArea>
<placeName><region type="state">Texas</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hotez, Peter J" sort="Hotez, Peter J" uniqKey="Hotez P" first="Peter J" last="Hotez">Peter J. Hotez</name>
<affiliation wicri:level="2"><nlm:affiliation>Texas Children's Hospital Center for Vaccine Development, Departments of Pediatrics, Baylor College of Medicine, Houston, TX, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Texas Children's Hospital Center for Vaccine Development, Departments of Pediatrics, Baylor College of Medicine, Houston, TX</wicri:regionArea>
<placeName><region type="state">Texas</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Bottazzi, Maria Elena" sort="Bottazzi, Maria Elena" uniqKey="Bottazzi M" first="Maria Elena" last="Bottazzi">Maria Elena Bottazzi</name>
<affiliation wicri:level="2"><nlm:affiliation>Texas Children's Hospital Center for Vaccine Development, Departments of Pediatrics, Baylor College of Medicine, Houston, TX, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Texas Children's Hospital Center for Vaccine Development, Departments of Pediatrics, Baylor College of Medicine, Houston, TX</wicri:regionArea>
<placeName><region type="state">Texas</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">Human vaccines & immunotherapeutics</title>
<idno type="eISSN">2164-554X</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">A SARS-CoV receptor-binding domain (RBD) recombinant protein was developed and manufactured under current good manufacturing practices in 2016. The protein, known as RBD219-N1 when formulated on Alhydrogel®, induced high-level neutralizing antibodies and protective immunity with minimal immunopathology in mice after a homologous virus challenge with SARS-CoV (MA15 strain). We examined published evidence in support of whether the SARS-CoV RBD219-N1 could be repurposed as a heterologous vaccine against Coronavirus Infectious Disease (COVID)-19. Our findings include evidence that convalescent serum from SARS-CoV patients can neutralize SARS-CoV-2. Additionally, a review of published studies using monoclonal antibodies (mAbs) raised against SARS-CoV RBD and that neutralizes the SARS-CoV virus <i>in vitro</i>
finds that some of these mAbs bind to the receptor-binding motif (RBM) within the RBD, while others bind to domains outside this region within RBD. This information is relevant and supports the possibility of developing a heterologous SARS-CoV RBD vaccine against COVID-19, especially due to the finding that the overall high amino acid similarity (82%) between SARS-CoV and SARS-CoV-2 spike and RBD domains is not reflected in RBM amino acid similarity (59%). However, the high sequence similarity (94%) in the region outside of RBM offers the potential of conserved neutralizing epitopes between both viruses.</div>
</front>
</TEI>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000393 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 000393 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= SrasV1 |flux= Main |étape= Merge |type= RBID |clé= pubmed:32298218 |texte= Potential for developing a SARS-CoV receptor-binding domain (RBD) recombinant protein as a heterologous human vaccine against coronavirus infectious disease (COVID)-19. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Merge/RBID.i -Sk "pubmed:32298218" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Merge/biblio.hfd \ | NlmPubMed2Wicri -a SrasV1
This area was generated with Dilib version V0.6.33. |